Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies
about
Big Data Offers Novel Insights for Oncolytic Virus ImmunotherapyPotential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus VariantsOverview of current immunotherapeutic strategies for gliomaMisdelivery at the Nuclear Pore Complex-Stopping a Virus Dead in Its TracksHigh-throughput screening to enhance oncolytic virus immunotherapyTrial Watch:: Oncolytic viruses for cancer therapyOncolytic viruses as anticancer vaccinesTumor-specific delivery of biologics by a novel T-cell line HOZOT.Going back to class I: MHC and immunotherapies for childhood cancer.Gene and cell therapy for pancreatic cancer.Role of cysteine-rich 61 protein (CCN1) in macrophage-mediated oncolytic herpes simplex virus clearance.Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacyGenome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells.CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy.A cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancer.Recent advances and future of immunotherapy for glioblastoma.Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trialWhole cell vaccination using immunogenic cell death by an oncolytic adenovirus is effective against a colorectal cancer model.Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity.Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses.The role of oncolytic virus immunotherapies to subvert cancer immune evasion.Fighting Cancer with Mathematics and Viruses.Developing immunotherapeutic strategies to target brain tumors.Immune System, Friend or Foe of Oncolytic Virotherapy?Oncolytic viruses: adenoviruses.Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models.Harnessing combined p19Arf and interferon-beta gene transfer as an inducer of immunogenic cell death and mediator of cancer immunotherapy.PiggyBac as a novel vector in cancer gene therapy: current perspective.Recombinant Vaccinia Viruses Coding Transgenes of Apoptosis-Inducing Proteins Enhance Apoptosis But Not Immunogenicity of Infected Tumor Cells.A cross-talk network that facilitates tumor virotherapy.Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report.Rewiring cancer cell death to enhance oncolytic viro-immunotherapyOncolytic potency and reduced virus tumor-specificity in oncolytic virotherapy. A mathematical modelling approach.Healing after death: antitumor immunity induced by oncolytic adenoviral therapy.Nano-Pulse Stimulation is a physical modality that can trigger immunogenic tumor cell death.Recurrent glioma clinical trial, CheckMate-143: the game is not over yet.Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies.Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells.Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations.Viroimmunotherapy for Colorectal Cancer: Clinical Studies.
P2860
Q26767209-1D1A3E60-0C5A-4952-9019-697A12B50BE1Q26775033-A5E2486E-6FCB-4ED4-BE9A-B1BE619C7536Q26776345-2BBC4247-A092-4BF1-9350-F50FEEB3B232Q26801484-20CCE879-32CA-49E2-83DF-EB1F1F192BA7Q26823674-B5EE8CA7-0169-440B-AC1D-DEF02C24BC68Q27021951-8E107EB0-71AF-44D8-BB73-2DBF02486E84Q27025600-0E04B4A5-BFB0-40D1-B254-64A14392DFA9Q30830225-EBE86CAE-3FC2-4624-A9CF-81CFAF695564Q35117552-CE546969-C67B-4061-A724-11267481C755Q35541787-4B55B123-0998-4547-9C2F-B7CCD44BC45FQ35618563-721BC531-C4C4-45EF-A4CC-E43D0AF5C99EQ35657822-C884E5FD-56E0-4E29-A06D-6358924EE2E9Q35740932-8C2AB957-890F-447E-B198-E5E54E19FEF2Q36821243-A07053F1-AF50-40BD-83D8-DCA4DF38618DQ37086063-A5C18C56-01ED-4642-9809-0687BBEB020AQ37239071-E34B2B90-80A1-4C95-A8D0-46985BC0ECBBQ37429172-55045864-F305-4F35-ABC9-C4303807E942Q37502453-9EF4E2C9-C950-4768-B880-D61D5821B4FCQ37707676-2AC30A75-1599-4AD8-8F7E-5100D360E51FQ38241666-EDE5AA39-8342-49EE-ACEC-695A77D573B9Q38357137-65CB0565-0ED0-4917-A711-178F525A49D4Q38612646-E978E7E8-E7CC-4102-9C69-2E24F1729203Q38851464-8A29D927-4A73-448D-A2D6-B6F7CB0ADE0DQ39355854-3FD78D83-B33E-4AA7-A838-206B5839B428Q39432063-0673E7D2-936C-4BFE-93F1-E564356B1F01Q40064004-008F138F-F13C-43AA-BDA9-CDD65B7C38D2Q40206389-EA01EF6F-2466-42B6-9B14-46DA3A3D48A9Q40993465-11AAAA57-744C-4EC6-91D4-0E38E070E70BQ41688010-95917010-DB9C-47B3-8BE5-7F6FC3FF6D68Q41755608-6E59F055-7E9A-4101-BFAE-809009E04143Q41873286-C3EB3B5F-E11F-49B6-A324-E1C1AF510A78Q41909648-958638C2-8E99-4A83-851E-2AF167633D79Q41932925-042B75EA-D4BB-4143-B51A-891747AA9A95Q42008858-266C631D-15F0-48F8-A86D-E38BF064B75DQ42291172-708362D8-C327-4E58-AB17-99B49BFF6C0CQ47140355-7A864C5C-4557-41E7-AC18-A25DBD8527FAQ47557087-F5AC1034-9C0A-4403-B8CC-E66893F14BB5Q50423294-66B6790A-F060-4EC3-BB05-99D80E16546EQ54963955-D2845A2B-345F-42A3-BA20-FE18823E8C80Q55085114-B3F39FF1-9E7D-46B7-BA12-154AA42CF262
P2860
Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Oncolytic virotherapy and immu ...... ed cancer treatment strategies
@en
type
label
Oncolytic virotherapy and immu ...... ed cancer treatment strategies
@en
prefLabel
Oncolytic virotherapy and immu ...... ed cancer treatment strategies
@en
P2860
P356
P1433
P1476
Oncolytic virotherapy and immu ...... ed cancer treatment strategies
@en
P2093
Samuel T Workenhe
P2860
P304
P356
10.1038/MT.2013.220
P577
2013-10-19T00:00:00Z